Fundraising FoxAction Potential Venture Capital Ltd. — Full Portfolio
11 tracked investments · listed companies and verified rows first
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)inNadim Yared(Executive Officer, Director)inDean Bruhn-Ding(Executive Officer)inJohn Brintnall(Executive Officer)inLiz Galle(Executive Officer)Kevin Hykes(President, Chief Executive Officer & Director)in
Co-investorsABS VenturesNew Enterprise Associates (NEA)Treo Ventures, LlcWindham Capital PartnersYsios CapitalHatteras Venture Partners+1 more
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.
BiotechHealthtechMedical DevicesChanhassen, US
Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)
BoardKlaus Veitinger(Director)inImran Eba(Executive Officer)in
Board seatJuan-Pablo Mas· per SEC Form D
Co-investorsOrbiMedHealthQuest CapitalSamsara BioCapitalSV Health InvestorsBrightEdge
Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).
HealthtechMedical DevicesNew York, US
Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)
BoardPaul LaViolette(Director)in
Board seatImran Eba· per SEC Form D · $15M raise · filed Feb 2019
Co-investorsStar51 CapitalDeerfield Management CompanyEarlybird Venture CapitalSV Health Investors
Exo is a company backed by leading venture capital and corporate investors focused on innovative technologies, with particular emphasis on healthcare, bioelectronic medicines, materials science, and deep technology solutions.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Yusuf Haque(Founder)in
Board seatJuan-Pablo Mas· per SEC Form D · $10M raise · filed May 2025
Co-investorsBold Capital PartnersCreative VenturesPage One VenturesTDK VenturesIntel CapitalOSF Ventures+5 more
.jpeg){kind=logo}
Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder.
BiotechHealthtechMedical DevicesSan Jose, US
Alexander Yeh(Founder)inMilton M. Morris(Executive Officer, Director)inDave Van Meter(Chief Executive Officer)Steve Paul(Chief Commercial Officer)in
Board seatImran Eba· per SEC Form D
Co-investorsAlumni VenturesCerity Partners VenturesForeground CapitalPortfoliaTreo Ventures, LlcWindham Capital Partners+2 more
Saluda Medical develops the Evoke spinal cord stimulation (SCS) system, which records the spinal cord's physiologic response to stimulation using Evoked Compound Action Potentials (ECAPs).
Deep TechHealthtechMedical DevicesBloomington, US
Greg Plamondon(Executive Officer)inKristin Caplice(Executive Officer)inBarry Regan(Executive Officer, Director)inJames Schuermann(Director, Executive Officer)Geoffrey Kinghorn(Director)
Board seatJuan-Pablo Mas· per SEC Form D
Co-investorsWellington ManagementFidelity InvestmentsREDMILET. Rowe Price
SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs.
BiotechHealthtechMedical DevicesValencia, US
Murthy Simhambhatla(CEO)inDavid Chernoff(Chief Medical Officer (MD))Yaakov Levine(PhD)inRohan Seth(Executive Officer)inKevin Tracey(Founder)
Board seatJuan-Pablo Mas· per SEC Form D
Co-investorsAlly Bridge GroupNew Enterprise Associates (NEA)Norwest Venture PartnersTopspin PartnersAsahi Kasei Corporate Venture CapitalCatalio Capital Management, LP+8 more
Cala Health develops non-invasive prescription therapies for movement disorders, starting with a treatment for hand tremor and essential tremor.
Deep TechDigital HealthHealthtechMedical DevicesSilicon Valley, US
Kate Rosenbluth, PhD(President & Chief Innovation Officer)Kate Rosenbluth(Founder)inDeanna Harshbarger(Founder)in
Co-investorsAlumni VenturesAscension VenturesGlobal BrainGV (Google Ventures)Lightstone VenturesLux Capital+5 more
Co-investorsCWRU Technology VenturesShangBay Capital LLC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CALA HEALTH, INC.Gradient Denervation Technologies
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.